Slides
Page 1
Third Quarter 2026 Financial Results and Recent Portfolio Execution O C T O BE R 27, 2026
Page 2
Agenda Introduction | Sanj K. Patel, Chief Executive Officer Third Quarter 2026 Financial Results | Mark Ragosa, Chief Financial Officer Closing Remarks | Sanj K. Patel, Chief Executive Officer Q&A Session 2 ARCALYST® Commercial Execution | Ross Moat, Chief Operating Officer
Page 3
Forward Looking Statements 3 This presentation (together with any other statements or information that we may make in connection herewith) contains forward-looking statements with respect to Kiniksa Pharmaceuticals International, plc (and its consolidated subsidiaries, collectively, unless context otherwise requires, “Kiniksa,” “we,” “us” or “our”). In some cases, you can identify forward looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “goal,” “design,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential,” “strategy,” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these identifying words. All statements contained in this presentation that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation, statements regarding our strategy; potential value drivers; potential indications; potential market opportunities and competitive position; market trends and dynamics; ongoing, planned and potential clinical trials and other studies; timing and potential impact of clinical data; regulatory and other submissions, applications and approvals; commercial strategy and commercial activities; expected run rate for our cash, cash equivalents and short-term investments; expected funding of our operating plan; financial guidance; and capital allocation. These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties, and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, without limitation, the following: delays or difficulty in enrollment of patients in, and activation or continuation of sites for, our clinical trials; delays or difficulty in completing our clinical trials as originally designed; potential for changes between final data and any preliminary, interim, top-line or other data from clinical trials, including the data from the interval analysis of our Phase 2 clinical trial of KPL-387 in recurrent pericarditis; our inability to replicate results from our earlier clinical trials or studies; impact of additional data from us or other companies, including the potential for our data to produce negative, inconclusive or commercially uncompetitive results; potential undesirable side effects caused by our products and product candidates; our inability to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities; potential for applicable regulatory authorities to not accept our filings, delay or deny approval of any of our product candidates or require additional data or trials to support approval; our reliance on third parties as the sole source of supply of the drug substance and drug product used in our products and product candidates; raw material, important ancillary product and drug substance and/or drug product shortages; our reliance on third parties to conduct research, clinical trials, and/or certain regulatory activities for our product candidates; complications in coordinating requirements, regulations and guidelines of regulatory authorities across jurisdictions for our clinical trials; business development activities and their impact on our financial performance and strategy; changes in our operating plan, business development strategy or funding requirements; existing or new competition; current and future healthcare reforms, including those affecting the delivery of or payment for healthcare products and services; and the impact of global economic policy, including any uncertainty in national and international markets. These and the important factors discussed in our filings with the U.S. Securities and Exchange Commission, including under the caption “Risk Factors” contained therein could cause actual results to differ materially from those indicated by the forward-looking statements made in this presentation. These forward-looking statements reflect various assumptions of Kiniksa's management that may or may not prove to be correct. No forward-looking statement is a guarantee of future results, performance, or achievements, and one should avoid placing undue reliance on such statements. Except as otherwise indicated, this presentation speaks as of the date of this presentation. We undertake no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. This presentation also contains estimates, projections, and/or other information regarding our industry, our business and the markets for certain of our product candidates, including data regarding the estimated size of those markets, and the incidence and prevalence of certain medical conditions. Unless otherwise expressly stated, we obtained this industry, business, market and other data from reports, research surveys, clinical trials, studies and similar data prepared by market research firms and other third parties, from industry, medical and general publications, and from government data and similar sources. Information that is based on estimates, forecasts, projections, market research, or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances reflected in this information. ARCALYST® is a registered trademark of Regeneron Pharmaceuticals, Inc.
Page 4
Introduction Sanj K. Patel Chief Executive Officer
Page 5
Q3 2026 Business Highlights Q3 2026 ARCALYST revenue of $286.0M Continued growth potential with only ~23% penetration into multiple recurrence population1 Full year 2026 net revenue guidance raised to between $1.045-$1.050 billion from previous guidance of $930- $945 million KPL-387 pivotal Phase 3 trial, PASTORALE, enrolling & dosing patients Phase 3 data expected in 2H 2027 KPL-1161 Phase 1 first-in- human trial on track to initiate by YE 2026 Strong financial position with ~$569M in cash Current operating plan expected to remain cash flow positive on an annual basis Financial strength provides capacity to continue investing in value creating opportunities Driving ARCALYST Revenue Advancing Clinical Portfolio Maintaining Financial Strength 5 1) As of Q3 2026
Page 6
6 Expanding Adoption of IL-1α & IL-1β Inhibition Driving ARCALYST Sales Increased penetration of multiple recurrence patient population to ~23% as of the end of Q3 2026 ~1,100 >2,550 Q3 2021 Q3 2022 Q3 2023 Q3 2024 Q3 2025 Q3 2026 Prescribers with 1 Recurrent Pericarditis Prescription Prescribers with ≥2 Recurrent Pericarditis Prescriptions Total and Repeat Prescribers of ARCALYST for Recurrent Pericarditis Patients ~800 ~150 ~360 ~640 ~1,070>650 >3,825 >1,450 ~1,275 ~1,640 ~1,625 >5,450 ~40 >200 ~450 Year-Over-Year Net Revenue Growth $12.1M $33.4M $54.5M $112.2M $180.9M $286.0M Q3 2021 Q3 2022 Q3 2023 Q3 2024 Q3 2025 Q3 2026
Page 7
2026 ARCALYST Net Product Sales Guidance Revenue guidance raised to $1.045-$1.050B from $980-$995M 7 1) 2021 = 9 months of availability (Q2-Q4). $38.5M1 $122.5M $233.2M $417.0M $677.6M 2021 2022 2023 2024 2025 2026 $1.045-1.050B Expected Net Product Sales Position ARCALYST as 2nd line Standard of Care Deepen penetration into 2+ recurrence population Drive adoption among larger 1st recurrence population
Page 8
ARCALYST Commercial Execution Ross Moat Chief Operating Officer
Page 9
Recurrence Number Opportunity for ARCALYST Growth Remains High Across RP Population Commercial success to date validates investments that are expanding reach and frequency to more patients 9 Data-Driven Strategy Aimed at Increasing Reach and Adoption ➢ Sales infrastructure focused on educating the large pool of HCPs who see recurrent pericarditis patients ➢ Positioning field resources at the right place and time, with the right messaging ➢ Building on early DTC success to efficiently extend reach % of Physicians Considering ARCALYST by Recurrence1 29% 54% 33% 69% 40% 67% 51% 80% 1st 2nd 2023 2024 2025 2026 (n= 200 Cardiologists / Rheumatologists) 1) HCP market research 2026; Kiniksa data on file HCP = Healthcare Professionals Positive trend in physicians considering ARCALYST earlier in the disease course, including on 1st recurrence 26% 35% 35% 51% 2023 2024 2025 2026 % of Physicians Putting ARCALYST Before Corticosteroids1 (n= 200 Cardiologists / Rheumatologists) Positive trend in physicians stating ideal position in line of therapy is before corticosteroids
Page 10
Heart’s Home DTC Campaign is Showing Strong Signals of Success 10 ARCALYST is prescribed ~80% of the time when requested by a patient3 Market Research Findings1 • ~20% of patients recall seeing the ARCALYST ad since its launch • >50% of patients seeing the ad indicated they visited the brand website for more information • ~55% of patients agreed strongly that the ad made them want to speak with their doctor about ARCALYST 1) Patient market research survey; Kiniksa data on file; 2) Google analytics data; 3) Kiniksa data on file (HCP survey) Website Activity Improvements2 • 12x increase in weekly visits to ARCALYST.com relative to pre-DTC period • 8x increase in engaged visits where visitor spends more time and/or completes a key site action • Increases in site traffic observed as new channel partners added to campaign and spend scaled
Page 11
Third Quarter 2026 Financials Mark Ragosa Chief Financial Officer
Page 12
12 Income Statement Three Months Ended September 30, 2026 2025 Product Revenue $286.0M $180.9M License and Collaboration Revenue $0.0M $0.0M Total Revenue $286.0M $180.9M Cost of Goods Sold $27.8M $20.3M Collaboration Expenses1 $105.8M $63.3M Research and Development $32.8M $24.2M Selling, General and Administrative $65.4M $49.1M Total Operating Expenses $231.7M $156.8M Operating Income $54.2M $24.0M Other Income, Net $4.8M $3.1M Income Tax Provision ($11.7M) ($8.7M) Net Income $47.3M $18.4M Collaboration Expenses1 Three Months Ended September 30, 2026 2025 ARCALYST Net Sales $286.0M $180.9M Profit Split-Eligible Cost of Goods Sold ($26.2M) ($20.0M) Commercial, Marketing, Regulatory and Other Expenses ($48.2M) ($34.3M) ARCALYST Collaboration Operating Profit $211.6M $126.6M ARCALYST Collaboration Expense $105.8M $63.3M ARCALYST Out-Licensing2 $0.0M $0.0M Other Collaboration Expenses $0.0M $0.0M Total Collaboration Expenses $105.8M $63.3M Balance Sheet September 30, 2026 December 31, 2025 Cash, Cash Equivalents and Short-term Investments $568.8M $414.1M Figures represented to the nearest tenth; totals may not sum exactly due to rounding. 1) Subject to the terms of the definitive agreements between Kiniksa and Regeneron; 50% of ARCALYST Collaboration Operating Profit plus 50% of ARCALYST Licensing Proceeds; 2) Revenue associated with ARCALYST Out -Licensing is included in License and Collaboration Revenue. Third Quarter 2026 Financial Results ARCALYST Net Revenue Guidance: $1.045-$1.050B R&D Expense Guidance: $160-$170M SG&A Expense Guidance: $270-$280M Full Year 2026 Financial Guidance
Page 13
Closing Remarks Sanj K. Patel Chief Executive Officer
Page 14
Third Quarter 2026 Financial Results and Recent Portfolio Execution O C T O BE R 27, 2026